BDTX (Black Diamond Therapeutics) Net Margin %: 0.00% (As of Mar. 2026)


BDTX Black Diamond Therapeutics Inc BDTX
38 GF Score
Price $1.71
! 2 Warning Signs
View Full Analysis

What is Black Diamond Therapeutics Net Margin %?

Black Diamond Therapeutics BDTX +0.59% 38 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates BDTX with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 946 Biotechnology companies, Black Diamond Therapeutics ranks worse than 105708.14% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Black Diamond Therapeutics's Net Income for the three months ended in Mar. 2026 was $-9.04 Mil. Black Diamond Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Black Diamond Therapeutics's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Black Diamond Therapeutics's Net Margin % or its related term are showing as below:


BDTX's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.815
* Ranked among companies with meaningful Net Margin % only.

Black Diamond Therapeutics  (NAS:BDTX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Black Diamond Therapeutics Net Margin % Related Terms

Black Diamond Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Black Diamond Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Black Diamond Therapeutics Net Margin % Chart

Black Diamond Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 31.95

Black Diamond Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.77 0.00 0.00 0.00 0.00

BDTX vs GUTS, ALPS, ONCY: Net Margin % Comparison

For the Biotechnology subindustry, Black Diamond Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Black Diamond Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Black Diamond Therapeutics's Net Margin % falls into.


BDTX
38GF Score
Black Diamond Therapeutics Inc BDTX
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Black Diamond Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Black Diamond Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=22.367/70
=31.95 %

Black Diamond Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-9.036/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Black Diamond Therapeutics (BDTX) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Black Diamond Therapeutics and its competitors. Over the past decade, Black Diamond Therapeutics' Net Margin % has ranged from 31.95 to 31.95. According to the industry distribution chart, Black Diamond Therapeutics ranks #999999 out of 946 companies in the Biotechnology industry.
Is Black Diamond Therapeutics' Net Margin % too high?
Black Diamond Therapeutics' current Net Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 31.95 to a high of 31.95. Based on the distribution chart, Black Diamond Therapeutics ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Black Diamond Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Black Diamond Therapeutics' Net Margin % compare to GUTS and ALPS?
According to the Biotechnology industry distribution chart, Black Diamond Therapeutics ranks #999999 out of 946 companies for Net Margin %. This places Black Diamond Therapeutics in the lower half of its industry. Historically, Black Diamond Therapeutics' own Net Margin % has ranged from 31.95 to 31.95 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Black Diamond Therapeutics and its competitors. Black Diamond Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Black Diamond Therapeutics stock overvalued right now?
Black Diamond Therapeutics (BDTX) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Black Diamond Therapeutics' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Black Diamond Therapeutics (BDTX), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Black Diamond Therapeutics Business Description

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
38GF Score

Get the complete analysis for BDTX

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price